ELEKTA CHOSEN TO DELIVER SOPHISTICATED BRAIN MAPPING TECHNOLOGY TO THE MIND RESEARCH NETWORK

ELEKTA CHOSEN TO DELIVER SOPHISTICATED BRAIN MAPPING TECHNOLOGY TO THE MIND
RESEARCH NETWORK

Press Release 
Stockholm, Sweden, April 17, 2009

The Mind Research Network (MRN) will bring world-leading technology to
Albuquerque, with the acquisition of an Elekta Neuromag®, a device for
non-invasive measurement of brain activity using Magnetoencephalography (MEG)
technology. 

MRN has been utilizing MEG technology to study brain function and disorders for
approximately the last five years; however, the organization will upgrade to the
Elekta Neuromag MEG system in early 2009, allowing researchers to record human
brain activity better and more accurately than before.

“When looking to replace our current MEG system, we chose Elekta because we felt
that their data collection software and analysis and archiving of records would
meet all of our research and clinical needs,” says Michael Weisend, Ph.D.,
director of MEG/EEG Core at MRN, and expert in identifying and specifically
defining the location of epileptic seizures.

“We are funded to study a variety of neuroscience areas that will exploit the
Elekta Neuromag's capability,” says Weisend. “Currently, we investigate the
fundamental mechanisms of learning and memory in healthy individuals, as well as
those with brain-based disorders such as traumatic brain injury, epilepsy, drug
addiction, and schizophrenia. We also are collaborating with Dr. Bruce Fisch,
director of the epilepsy treatment program at the University of New Mexico to
develop a clinical MEG program. This program will help to guide neurosurgical
intervention in people with epilepsy and brain tumors.” "With a long-term commitment to the development of MEG technology, Elekta was
the natural choice when MRN made its decision to purchase a new MEG system,"
says Stephen Otto, Chairman of Elekta's Neuromag Business. "We are pleased to
see an increasing interest around the world for Elekta Neuromag systems,
particularly in the U.S. We will continue to develop new features and
technological advances so that organizations like MRN can continue to be at the
forefront of MEG instrumentation."

MEG technology is regarded as the most efficient method for tracking brain
activity at millisecond resolution. Compared to EEG technology, MEG has uniquely
accurate localization capabilities. Other technologies such as Computed
Tomography (CT) and Magnetic Resonance Imaging (MRI), only provide anatomical or
metabolic information; whereas MEG is a direct measure of neuronal electric
activity. When complemented with MRI, MEG increases the ability to understand
brain activity and improve treatment of functional disorders particularly,
epilepsy.

For further information, please contact:

Lena Schattauer, Investor Relations, Elekta AB
Tel: +46 8 587 257 22, +46 70 595 51 00, e-mail: lena.schattauer@elekta.com   

For clinical, scientific or sales inquiries, please contact:

Michael Enwall, Director, MEG Marketing Europe & AFLAME
Tel: +46 8 587 25 448, e-mail: michael.enwall@elekta.com

Gordon Haid, Director of Sales, North America, Functional Mapping Business Unit
Tel: +1-604-395-5339, e-mail: gordon.haid@elekta.com


About The Mind Research Network

The Mind Research Network (MRN) is an independent non-profit organization
dedicated to the discovery and advancement of clinical solutions for the
prevention, diagnosis and treatment of mental illness and brain disorders.

Headquartered in Albuquerque, New Mexico, MRN consists of an interdisciplinary
association of scientists who are focused on imaging technology and its
emergence as an integral element of neuroscience investigation. With an extended
community of researchers, academicians, graduate students and technicians, MRN
is uniquely positioned with its national infrastructure to link the brightest
minds in neuroscience with some of the most advanced neuroimaging capabilities
in the world today. For additional information, visit www.mrn.org.

About Elekta

Elekta is a human care company pioneering significant innovations and clinical
solutions for treating cancer and brain disorders. The company develops
sophisticated state of the art tools and treatment planning systems for
radiation therapy and radiosurgery, as well as workflow enhancing software
systems across the spectrum of cancer care.

Stretching the boundaries of science and technology, providing intelligent and
resource-efficient solutions that offer confidence to both healthcare providers
and patients, Elekta aims to improve, prolong and even save patient lives,
making the future possible today.

Today, Elekta solutions in oncology and neurosurgery are used in over 5,000
hospitals globally, and every day more than 100,000 patients receive diagnosis,
treatment or follow-up with the help of a solution from the Elekta Group.

Elekta employs around 2,500 employees globally. The corporate headquarter is
located in Stockholm, Sweden, and the company is listed on the Nordic Exchange
under the ticker EKTAb. For more information about Elekta, please visit
www.elekta.com.